ArticleJournal of inflammation research2026
Nomogram for Predicting Regression of Persistent Coronary Artery Aneurysms in Kawasaki Disease: A Three-year Follow-up Cohort Study in Southwest China.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Coronary artery aneurysm (CAA) is a potentially life-threatening cardiovascular complications in Kawasaki disease (KD). This study aimed to construct and then validate a prognostic model to assess the likelihood of persistent CAA regression in KD. Methods: Using Cox regression analysis, we constructed a prognostic nomogram model to estimate the probability of CAA regression at one-year, two-year, and three-year intervals in KD patients with CAA, followed by temporal external validation. The model's discriminative ability, calibration, and potential clinical benefit were evaluated by the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Results: A total of 658 KD with CAA were finally included. From January 2012 to July 2021, 557 participants were enrolled and subsequently allocated into a training set (n = 390) and a testing set (n = 167) using a 7:3 random split. The temporal external validation cohort consisted of 101 cases diagnosed as KD with CAA between August, 2021 and July, 2022. Four variables were retained in the final prognostic model: age at diagnosis (HR = 0.994, 95% CI 0.990-0.998); CAA enlargement category (reference: SCAA; MCAA: HR = 0.398, 95% CI 0.299-0.530; GCAA: HR = 0.058, 95% CI 0.027-0.125); platelet count (HR = 0.999, 95% CI 0.998-1.000); and fibrinogen level (HR = 1.143, 95% CI 1.042-1.255). The model demonstrated robust discriminative performance, with AUCs of 0.854, 0.919, and 0.910 at one, two, and three years in the training set; 0.844, 0.910, and 0.913 in the testing set; and 0.763, 0.886, and 0.986 in the external validation cohort. Conclusion: We established a prognostic model capable of estimating the long-term outcomes in KD, and confirmed its favorable performance in terms of discrimination, calibration, and potential value for clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.